These findings demonstrate that NK1R is a potential synthetic lethal partner of CaMKII to eradicate GSCs, and they suggest that the combination treatment of CaMKII and NK1R inhibitors can be utilized as a powerful therapeutic strategy to overcome resistance to chemotherapy and GBM recurrence. This evidence concerns the gene CAMK2G and glioblastoma.